Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marqeta Inc (MQ) vs 10X Genomics Inc (TXG) Price & Performance

Marqeta IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Marqeta Inc vs 10X Genomics Inc — how do they compare? Marqeta Inc trades at $15.59 (market cap $1.62B), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 4.7× Marqeta Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.

MQTXG
Market Cap
$1.62B$7.61B
Sector
TechnologyHealth
52-Week High
$26.00$58.57
52-Week Low
$15.04$11.34
Enterprise Value
$935.36M$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marqeta Inc

Marqeta (MQ) trades at $15.62, up 0.13% with a bearish technical outlook. The company shows improving fundamentals with Q2 2026 revenue growth of 17% and second consecutive GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion, while a 4:1 reverse stock split was completed in July 2026. Valuation remains elevated with a P/E of 173, though analyst consensus targets $19.00 with 32% buy ratings.

The outlook suggests cautious optimism as Marqeta transitions to profitability amid competitive fintech pressures. Key risks include execution on new initiatives and maintaining growth momentum. Upside potential exists if recent partnerships drive sustained revenue acceleration, but high valuation multiples require continued strong performance to justify.

10X Genomics Inc

TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.

Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.

Returns comparison

Trailing returns across standard periods

About Marqeta Inc

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Read more on MQ

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG